CombiMatrix Corporation (NASDAQ:CBMX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

17

CombiMatrix Corporation (NASDAQ:CBMX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02.

Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On June 19, 2017, to the authority granted under the CombiMatrix
Corporation 2006 Stock Incentive Plan, the Compensation Committee
of CombiMatrix Corporation (the Company) approved an amendment
and restatement of the Companys 2017 Executive Performance Bonus
Plan (the 2017 Bonus Plan) that was adopted on January 31, 2017
and previously disclosed in the Companys Current Report on Form
8-K filed with the Securities and Exchange Commission on February
3, 2017. The amendment and restatement of the 2017 Bonus Plan
modifies the bonus payment schedule thereunder such that (i) if
semi-annual bonus targets are achieved, the semi-annual cash
bonus payments will be paid once the Companys June 30, 2017
financial statements are prepared and reported to the
Compensation Committee, and will be paid out within seventy-five
days following June 30, 2017; and (ii) if annual bonus targets
are achieved, the annual cash bonus payments will be paid once
the Companys auditors have completed their annual audit of the
Companys consolidated financial statements, and will be paid out
within seventy-five days following December 31, 2017. In order to
receive a bonus payment, the participant must be employed by the
Company or its subsidiary at the time bonuses are computed and
distributed.

The foregoing information is qualified in its entirety by
reference to the actual terms of the Amended and Restated 2017
Bonus Plan attached hereto as Exhibit 10.1 and which is
incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security
Holders.

CombiMatrix Corporation (the Company) held its 2017 annual
meeting of stockholders on June 14, 2017. The following proposals
were approved according to the following final voting results:

To elect the six (6) directors named in the proxy statement to
serve until the 2018 annual meeting of stockholders and until
their successors have been duly elected and qualified:

Director Candidate For Withheld Broker Non-Votes
Robert E. Hoffman 648,298 143,509 1,078,541
R. Judd Jessup 653,887 137,920 1,078,541
Jeremy M. Jones 645,631 146,176 1,078,541
Mark McDonough 737,006 54,801 1,078,541
Dirk van den Boom, Ph.D. 740,076 51,731 1,078,541
Lle White 734,390 57,417 1,078,541

To approve the amendment and restatement of the Companys 2006
Stock Incentive Plan to increase the number of shares of common
stock available for grant thereunder by 400,000 shares, from
200,000 shares to 600,000 shares, and to effect various other
changes thereunder, as described in the proxy statement:

For 499,488
Against 289,667
Abstain 2,652
Broker Non-Votes 1,078,541

To ratify the appointment of Haskell White LLP as the Companys
independent registered public accounting firm for 2017:

For 1,847,019
Against 12,194
Abstain 11,135
Broker Non-Votes
Item 9.01. Financial Statements and Exhibits.

(a) Not Applicable.

(b) Not Applicable.

(c) Not Applicable.

(d) Exhibits.

10.1 Amended and Restated 2017 Executive Performance Bonus Plan



CombiMatrix Corp Exhibit
EX-10.1 2 ex10-1.htm   Exhibit 10.1   COMBIMATRIX CORPORATION   AMENDED AND RESTATED 2017 EXECUTIVE PERFORMANCE BONUS PLAN   Purpose   Pursuant to the authority granted under CombiMatrix Corporation Compensation Committee Charter,…
To view the full exhibit click here
About CombiMatrix Corporation (NASDAQ:CBMX)

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

An ad to help with our costs